Optimal Embeddedness and Governance in Biotech Venture Capital Syndicates

The biotech venture market faces intense capital demands and regulatory scrutiny, yet academic research on VC networks remains rooted in software and consumer-tech contexts. This dissertation investigates how repeated co-investment ties and domain-expertise homophily influence a venture's exit likelihood, timing, and route amid the sector's pronounced technological and market uncertainty. Using a novel panel of 11,680 biotechnology start-ups from the United States, Canada, and Europe (2010-2024), we apply pooled logit, Cox proportional-hazards, multinomial logit, and Fine-Gray competing-risk models. Our findings show that both average prior co-investment and investor homophily exhibit robust inverted-U relationships with exit outcomes. Moderate familiarity and scientific overlap maximize exit probability, while either sparse or excessive embedding reduces success. Governance mechanisms also play a crucial role: participation of a pharmaceutical corporate VC or a highly independent board flattens the negative effects of over-embedding, enabling syndicates to sustain exit momentum at higher levels of familiarity or homogeneity. Furthermore, the optimal degree of embeddedness is route-specific: IPOs require deeper coordination than trade sales, while acquisitions peak earlier and are less sensitive to homophily. These findings refine network-embeddedness theory in the life-science context, identify governance contingencies, and offer practitioners quantitative metrics to balance trust, expertise, and oversight in biotech financing.